Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
https://drive.google.com/file/d/1a5M9mWhRXGFj3Vk4ZPwQMkQ0DeE8omH6/view?usp=drivesdk
Great analysis and understanding of the high placebo results that we all were sort of questioning when the results came out last year. Nice positive RNS and great focus on US results...hopefully it's seen across the pond for that NASDAQ listing To push 4D and LBPS up.
Does any of the below look new to anyone? I can't see anything new from what was announced when phase 2 trails were completed, but maybe everything hasn't been released yet and wait for the presentation at 5pm to find out.
Conclusions
Single strain Live Biotherapeutic Blautix demonstrated activity in both IBS-C and IBS-D, including a particularly strong effect on bowel habit, and excellent safety profile. Further analyses ongoing to support Phase III pivotal trial design.
https://ddw.org/attendee-planning/online-planner/
Search for BLAUTIX
So I went on the DDW website to view when the presentation will be. It's at 12.15 to 1pm EST today. So about 5pm UK time if I am that right. Also, I found the paper attached to the presentation. So below:
A PHASE II STUDY OF LIVE BIOTHERAPEUTIC BLAUTIX IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH SUBTYPES IBS-D AND IBS-D
Presentation Number: Sa607
Background
Current treatments target subset-specific symptoms of IBS with constipation (IBS-C) or diarrhoea (IBS-D). Blautix (Blautia hydrogenotrophica) is a human gut microbiome-derived, oral Live Biotherapeutic, with potential as a disease-modifying therapy for IBS, addressing functional microbiota abnormalities.
To evaluate the clinical efficacy of Blautix and to define key parameters for a pivotal program we conducted a Phase II randomised, double blind, placebo-controlled, parallel group, multi-center, study in patients with IBS-C or IBS-D.
Methods
353 pts with IBS-C or IBS-D with eligible baseline data (158 and 195 pts respectively) were randomised 1:1 to receive Blautix or placebo BID for 8 weeks, with 4 week follow-up period.
The primary endpoint was overall responder rate (ORR) in IBS-C or IBS-D cohorts in the Full Analysis Set (N=353). Overall responders must have improvement in weekly symptoms (abdominal pain intensity and stool frequency (IBS-C) or consistency (IBS-D)) for =50% of treatment period. ORR was also assessed in the combined IBS-C/D group and the Efficacy Evaluable Analysis Set (N=319) - all pts who completed the 8-week treatment and assessment period without major protocol violations, identified in a blinded data review.
Secondary and exploratory endpoints include bowel habit (stool frequency or consistency) and abdominal pain independently, fecal microbiota analysis, and safety. Pearson’s test with Yates’ correction was used to calculate P values, no corrections were made for multiple testing. Study was designed to demonstrate statistical difference at a one-sided P value <0.1 at a placebo response rate of 40%.
Results
The number of IBS-C and IBS-D pts receiving Blautix or placebo who were overall responders are shown in Table 1.
The number of IBS-C and IBS-D pts receiving Blautix or placebo with overall improvement in bowel habit are shown in Table 2.
In the EEAS overall improvement in abdominal pain occurred in 33.8% IBS-C pts receiving Blautix vs 24.4% placebo (P=0.2), and 49.4% vs 42.7%, respectively, in IBS-D pts (P=0.236). Analsysis of the combined IBS-C/D group showed overall improvement in abdominal pain in 42.1% for Blautix vs 34.1% for placebo (P=0.069).
Further work is ongoing in relation to exploratory and subgroup analyses.
Blautix showed a highly favourable safety profile with no treatment related SAEs. Across Blautix and placebo treatment groups respectively, 32.8% and 33.0% pts experienced AE(s).
Depends on the time graph of the chart (1min, 5min, 1 hr, 1 day etc). The chart probably misses the high because of the tick interval in place. The 52 week high was definitely 183.
I think everyone needs to calm down about the delisting...if it was being delisted and moved to Nasdaq it would of been advised as part of the deal. What is currently being done is simply a reverse takeover or SPAC listing - thus dual listing. Now in the future they might decide there is no need for UK listing - or it is detrimental (not sure why that would be as more capital) - then they will advise. At the moment I am pretty comfortable with this stock being in my ISA and will play it when and if it happens. Worrying about this now is not very beneficial.
Why would it be ineligible for ISA if delisted from AIM? Not sure I understand the regulatory restriction on this given other US only stocks can be held in ISA?
ok then...guess i was wrong...here we go!!!
lol i am just being realistic here. My average is 5.7p so definitely dont want to deramp but come £1, seriously! We are at 6p. Its struggled twice to get past 6.5p so I am looking at a close above that and than 10p. £1 maybe in like 6 months but if it hits that soon I will be very happy but surprised.
yes but the number of shares on issue are much more than at IPO....
To compare Eve Sleep with KNB - a specific medicinal cannabis play that has just IPO'd is crazy. The rampers are out on this board after days of being quiet. Also not sure how you see us moving to £1 anytime soon.....these rampers on this chat today honestly.
EliteTrader - this announcement was made 3rd Feb...not sure why you are reposting now....
Market definitely loves the CBD venture....or is something else going on. Great day finally!!
Yeah pretty excited about these miners - i missed the boat with Tesla (I am in NIO though) and think like Covid, the real winners will be the ones that supply the equipment. I am hoping it stays around this 80p mark until end of next week (highly unlikely) as it will hit £1 if it breaks that for sure. Congrats for those long term holders or those who jumped in mid last year. Very exciting times. When you consider all the EV cars that are being released this year but the mainstream petrol cars, miners will have a big year!
Hey guys, I have just started reviewing lithium miners/miners associated with EV batteries and this seems to be one of the best. Invested in Euro Manganese and Vulcan in ASX. Thinking about getting into this next week when i get some cash in - thoughts on the upside given the moves since November and that it has hit its historic high now.
This from the Guardian....next few months might be tough on stocks (not just eve) but will get through it...
"Morgan Stanley: FTSE 250 to plunge 10% on no-deal Brexit
Morgan Stanley has warned that the domestically-focused FTSE 250 could tumble by as much as 10% if the UK crashed out of the EU without a deal at the end of December.
The impact would be even worse for UK-listed banks, which are expected to plunge between 10-20%, due to fears that the Bank of England could introduce negative interest rates to try encourage lending and spending across the country.
A research note from the US investment bank admits that most forecasts have factored in some kind of free trade agreement.
A no-deal Brexit, however, “would represent a genuine and negative ‘surprise’ that markets are likely under-prepared for”, it warned.
Under a no-deal outcome we would expect little reaction in the FTSE100 given the support from GBP depreciation.
However, we would see potential for 6-10% underperformance from the FTSE250 and 10-20% downside for UK banks (given additional concerns around negative rates).
The other UK sectors most at risk would be:
Insurers
Real Estate
Housebuilders
Morgan Staley added that the biggest beneficiaries would be healthcare and consumers staples with high overseas exposure.